ACTS

ACT Biotech developed several small-molecule kinase inhibitors targeting key cancer pathways such as PDGFRβ/VEGF/c-Kit/FGF/ABL. Its lead program telatinib reached Phase 2 clinical trials for advanced gastric carcinoma but did not reach commercialization before the company's acquisition. The company was active primarily between its founding in 2008 until its acquisition post-late-stage clinical work around the early-to-mid 2010s. It had a lean team (~6 employees), raised approximately $12–26M from investors including Eddingpharm and NGN Capital, operated out of San Francisco with some presence also noted in New York City, and focused exclusively on oncology therapeutics addressing unmet needs.